Impact of TKIs post–allogeneic hematopoietic cell transplantation in Philadelphia chromosome–positive ALL | Zendy

Neeraj Saini | Zendy; David Marín | Zendy; Celina Ledesma | Zendy; Ruby Delgado | Zendy; Gabriela Rondón | Zendy; Uday Popat | Zendy; Qaiser Bashir | Zendy; Chitra Hosing | Zendy; Yago Nieto | Zendy; Amin M. Alousi | Zendy; Muzaffar H. Qazilbash | Zendy; Stefan O. Ciurea | Zendy; Elizabeth Shpall | Zendy; Issa F. Khouri | Zendy; Hagop M. Kantarjian | Zendy; Elias Jabbour | Zendy; Farhad Ravandi | Zendy; Richard E. Champlin | Zendy; Partow Kebriaei | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Impact of TKIs post–allogeneic hematopoietic cell transplantation in Philadelphia chromosome–positive ALL

Author(s) -

Neeraj Saini,

David Marín,

Celina Ledesma,

Ruby Delgado,

Gabriela Rondón,

Uday Popat,

Qaiser Bashir,

Chitra Hosing,

Yago Nieto,

Amin M. Alousi,

Muzaffar H. Qazilbash,

Stefan O. Ciurea,

Elizabeth Shpall,

Issa F. Khouri,

Hagop M. Kantarjian,

Elias Jabbour,

Farhad Ravandi,

Richard E. Champlin,

Partow Kebriaei

Publication year - 2020

Publication title -

blood

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 5.515

H-Index - 465

eISSN - 1528-0020

pISSN - 0006-4971

DOI - 10.1182/blood.2019004685

Subject(s) - transplantation , philadelphia chromosome , hematopoietic stem cell transplantation , medicine , stem cell , tyrosine kinase , immunology , biology , genetics , chromosomal translocation , gene , receptor

How to best use tyrosine kinase inhibitors (TKIs) of BCR-ABL after allogeneic stem cell transplantation for Philadelphia chromosome–positive acute lymphoblastic leukemia (ALL) is unknown but will almost certainly not be addressed by a definitive randomized trial. Saini and colleagues provide a large body of observational data to reinforce earlier circumstantial evidence favoring prophylactic use of TKIs for at least 2 years posttransplant.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research